Urinary pyridinium cross-links as markers of bone resorption in tumor-associated hypercalcemia

J Clin Endocrinol Metab. 1992 Mar;74(3):471-5. doi: 10.1210/jcem.74.3.1740478.


Osteoclastic activity is increased in tumor-associated hypercalcemia, which, thus, constitutes an excellent opportunity to assess new markers of the bone resorption rate. We have measured the fasting urinary excretion of the pyridinium cross-links pyridinoline (Pyr) and deoxypyridinoline (D-Pyr) in 36 hypercalcemic cancer patients (mean +/- SD, 3.2 +/- 0.4 mmol/L for total serum Ca and 1.66 +/- 0.24 mmol/L for Ca2+). Thirty-two of them were reevaluated after treatment with iv bisphosphonates. Urinary Pyr and D-Pyr levels were higher than those in healthy controls (130 +/- 62 vs. 40 +/- 19 nmol/mmol creatinine for Pyr and 20 +/- 15 vs. 6 +/- 3 nmol/mmol creatinine for D-Pyr; P less than 0.001 for both). This represented a mean 3.3-fold increase over the normal mean compared to 5.8- and 3.4-fold increases for fasting urinary Ca and hydroxyproline, respectively. Individual values were elevated in 83% and 75% of the cases for Pyr and D-Pyr compared to 97% and 83% for urinary Ca and hydroxyproline, respectively. The levels of Pyr and D-Pyr tended to be higher in patients with head and neck tumors than in patients with breast cancer. Urinary Pyr and D-Pyr correlated with each other (r = 0.72; P less than 0.001) and were highly correlated with hydroxyproline (r = 0.68 and 0.83, respectively; P less than 0.001 for both), but poorly correlated with urinary Ca (r = 0.21; P = NS and r = 0.42; P = 0.01, respectively), suggesting that these markers reflect different events of bone resorption. Similarly, after bisphosphonate therapy, urinary Pyr and D-Pyr levels fell by 31% and 50%, respectively, compared to 38% for hydroxyproline and 76% for urinary Ca. There was a significant correlation between posttreatment D-Pyr and serum Ca levels (r = 0.43; P less than 0.05). In summary, we found that the urinary excretion of Pyr and D-Pyr was markedly increased in hypercalcemic cancer patients and was adequately lowered by bisphosphonate therapy. The urinary excretion of the pyridinium cross-links, especially D-Pyr, should be helpful to specifically quantitate bone matrix resorption and monitor the inhibition of bone resorption in cancer patients receiving antiosteolytic drugs.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acids / urine
  • Biomarkers / urine
  • Bone Resorption / diagnosis
  • Bone Resorption / etiology
  • Bone Resorption / urine*
  • Breast Neoplasms / physiopathology
  • Calcium / blood
  • Female
  • Head and Neck Neoplasms / physiopathology
  • Humans
  • Hypercalcemia / drug therapy
  • Hypercalcemia / physiopathology*
  • Hypercalcemia / urine
  • Male
  • Middle Aged
  • Neoplasms / physiopathology*
  • Neoplasms / urine
  • Organophosphonates / therapeutic use


  • Amino Acids
  • Biomarkers
  • Organophosphonates
  • pyridinoline
  • deoxypyridinoline
  • Calcium